A long series of slow infusions removes lead and cadmium from the body — a step that measurably works. Whether removal changes arteries is unsettled: one large trial found fewer cardiac events, the trial built to confirm it found none. Supervised infusions were as well tolerated as placebo; deaths outside trials followed dosing errors and confusion between two similarly named products. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood lead | Below 1.0 µg/dL; lowest achievable is the functional target | Main vasculotoxic metal the therapy removes; sets expected yield |
| Urine cadmium | Below 0.3 µg/g creatinine | Second metal implicated in arterial injury; falls slowly |
| Serum creatinine and eGFR | eGFR at or above 75 mL/min/1.73 m² | Sets the dose and triggers pausing the course |
| Ionized calcium | 4.8–5.3 mg/dL | Tracks the mechanism behind the fatal cases directly |
| Red blood cell magnesium | 5.0–6.5 mg/dL | Chelated alongside target metals; low levels provoke arrhythmia |
| Serum zinc | 90–120 µg/dL | The essential mineral most depleted across a course |
| Serum copper | 80–100 µg/dL | Also chelated; deficiency causes anemia and neuropathy |
| Complete blood count | Hemoglobin 13.5–15.5 g/dL in men, 12.5–14.5 in women | Detects anemia from mineral depletion or marrow suppression |
| Urinalysis with protein | No protein and no casts | Earliest sign of tubular irritation, before creatinine moves |
| Blood pressure | 110–125 over 70–80 mmHg | Lead exposure raises it; infusions can lower it acutely |
| HbA1c | 5.0–5.4% | Diabetes defines the subgroup where any signal appeared |
Cadence: Full baseline panel before the first infusion. Creatinine and ionized calcium before infusion 5 and then every fifth infusion; magnesium, zinc and copper every tenth; urine metals at infusion 20 and at the final session. After the course, kidney function and mineral status at 3 months, then every 6 to 12 months for as long as any maintenance infusions continue.